Dissertations / Theses on the topic 'Abl2'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 dissertations / theses for your research on the topic 'Abl2.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Yang, Yi. "Signal transduction of abscisic acid in Arabidopsis thaliana identification and characterisation of protein interaction partners of ABl2 /." [S.l.] : [s.n.], 2003. http://deposit.ddb.de/cgi-bin/dokserv?idn=969393997.
Full textDE, MARCO SOFIA. "STUDY OF THE INTERACTIONS AMONG ARG/ABL2, TGF-β1 AND LOX IN CLEAR CELL RENAL CELL CARCINOMA PROGRESSION." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2020. http://hdl.handle.net/10281/263399.
Full textAbout 25-30% of clear cell Renal Cell Carcinoma (ccRCC) patients show an advanced stage of disease at the time of diagnosis, and about 30% of these patients have matastasis affecting bones. An involvement of TGF-β1 in promoting ccRCC aggressiveness, invasion and bone metastasis has been described. We previously showed that the extracellular matrix modifying enzyme lysyl oxidase (Lox), which promotes cell migration and invasion through cytoskeleton rearrangement, was overexpressed in ccRCC. Lox has a key role in formation of premetastatic bone lesions in breast and colon cancer through osteoclast activation and osteoblast inhibition. Previous data evidenced that TGF-β1 production is modulated by Arg tyrosine kinase in human renal tubular cells. Arg modulates, through cytoskeleton rearrangement, invasion and metastasis of breast and prostate cancers. Based on these data and using in vitro models of primary cell cultures and cell lines, we evaluated the molecular interactions among TGF-β1, Lox and Arg in ccRCC cells and the functional effects of these interactions on tumor invasion and osteoclast and osteoblast behavior responsible for premetastatic bone lesion formation. The expression and secretion of TGF-β1 and Lox, and Arg protein expression, were increased in ccRCC versus normal cortex primary cultures. In ccRCC cultures TGF-β1 and Lox secretion were positively correlated. TGF-β1 treatment of ccRCC 786-O cell line upregulated Lox expression and secretion and downregulated Arg protein level. The TGFβ-receptor inhibitor SB431542 reverted these effects. Inhibition of Smad-dependent TGF-β pathway by SIS3 and proteasome activity by MG132 rescued Arg protein level. Arg silencing by siRNA in 786-O cells induced an increment of TGF-β1 and Lox secretion, reverted by SB431542 treatment. Moreover, Arg silencing in 786-O cells decreased cell invasion analyzed by 3D invasion assay in collagen, even in presence of TGF-β1 treatment. TGF-β1 signalling inhibition with SB431542 reduced cell invasion even in Arg silenced cells. Treatment with 786-O conditioned media inhibited MC3T3-E1 osteoblast proliferation and increased osteoclastic differentiation of RAW264.7 cells, as evaluated by TRAP staining. Lox inhibitor βAPN partially reverted these effects. Preliminary results obtained using conditioned media of ccRCC primary cultures confirmed these observations. Overall, these data suggest that in ccRCC cells Arg modulates Lox production by secretion of TGF-β1 that, in turn, modulates Arg protein stability through a Smad-dependent pathway. The characterization of the complex interactions among TGF-β1, Lox and Arg, which modulate ccRCC cell invasion and osteoblast and osteoclast behavior involved in premetastatic bone lesion formation, can shed light on the molecular mechanisms of ccRCC progression.
ANGELONI, VALENTINA. "Studio e caratterizzazione delle isoforme della tirosino chinasi non recettoriale ARG nel differenziamento neuronale in vitro." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2010. http://hdl.handle.net/10281/7823.
Full textLee, Jennifer Kim. "A Novel Role for Abelson Tyrosine-Protein Kinase 2| Characterization of Abl2 in Regulating Myoblast Proliferation and Muscle Fiber Length." Thesis, New York University, 2017. http://pqdtopen.proquest.com/#viewpdf?dispub=10258043.
Full textSkeletal muscle generates contractile forces that allow the body to execute movements for walking, speaking and breathing. Although we understand a great deal about the steps of muscle formation, the mechanisms that control muscle size are poorly understood. Even less is known about how muscles interact with skeletal elements, including connective tissue, tendon and bone. This dissertation describes a novel role for Abelson tyrosine-protein kinase 2, a non-receptor tyrosine kinase, during muscle development. First, I characterize the defects in skeletal muscle of abl2 mutant mice and show that muscle fibers in the diaphragm and other muscles are extraordinarily long in abl2 mutant mice. As a consequence of expansion of the diaphragm muscle, the central tendon of the diaphragm is proportionally reduced in size. Second, I demonstrate that abl2 controls muscle size by regulating myoblast proliferation. Third, I show that Abl2 acts in myoblasts to attenuate their proliferation, thereby limiting myoblast fusion and muscle fiber size. Fourth, I show that the exercise endurance of abl2 mutant mice is diminished, likely due to the compensatory reduction in size of the diaphragm central tendon. Finally, I provide evidence for signaling between muscle cells and tendon cells that induces tendon cell differentiation.
Thai, Minh. "RIN1 activates ABL oncoproteins and its required for full BCR-ABL1 mediated transformation." Diss., Restricted to subscribing institutions, 2008. http://proquest.umi.com/pqdweb?did=1790313631&sid=11&Fmt=2&clientId=1564&RQT=309&VName=PQD.
Full textDasgupta, Yashodhara. "NORMAL ABL1 IS A TUMOR SUPPRESSOR AND THERAPEUTIC TARGET IN BCR-ABL1-POSITIVE LEUKEMIAS." Diss., Temple University Libraries, 2014. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/239008.
Full textPh.D.
BCR-ABL1 results from t(9;22)(q34;q11) reciprocal translocation resulting in BCR-ABL1 kinase expression, initiating chronic myeloid leukemia in chronic phase (CML-CP). At the initial stages of CML-CP both oncogenic BCR-ABL1 kinase and normal ABL1 kinase are expressed, however, loss of ABL1 kinase expression in CML-CP can result from an interstitial deletion in the normal chromosome 9 [del(9q34)] which may be combined with the transcriptional silencing of the alternative ABL1 promoter within the translocation eventually leading to disease progression and drug resistance. We found that BCR-ABL1 Abl1-/- cells generated a CML-blast phase (BP)-like disease phenotype in NOD-SCID mice compared to the BCR-ABL1 Abl1+/+ cells. To determine the mechanisms responsible for blastic transformation of BCR-ABL1 Abl1-/- cells, we examined the role of ABL1 in proliferation, differentiation, apoptosis, genomic instability, and stemness. The presence of ABL1 inhibited proliferation in BCR-ABL1 cells as BCR-ABL1 Abl1-/- cells had higher clonogenic activity and proliferative rate compared to their wild-type counterparts. ABL1 is essential for myeloid differentiation since BCR-ABL1 Abl1-/- cells showed an immature blast phenotype when stained with Wright-Giemsa and myeloid differentiation markers Gr-1 and CD11b. ABL1 promoted apoptosis in response to genotoxic stress as revealed by reduced clonogenicity and expression of p53, phosphoserine-15 p53 and activated caspase 3 in BCR-ABL1 Abl1+/+ compared to knock-out cells. Although the absence of ABL1 did not enhance ROS and oxidative DNA damage, it appears that an impaired DNA damage response may be responsible for higher chromosome numbers and an accumulation of high numbers of chromosomal aberrations in BCR-ABL1 Abl1-/- cells. We detected an expansion of Lin-c-Kit+Sca-1+ leukemia stem cells (LSCs) in BCR-ABL1 Abl1-/- cells compared to BCR-ABL1 Abl1+/+ or non-transformed counterparts; among the LSCs, there was a higher percentage of CD34-Flt3- long-term and CD34+Flt3- short-term stem cells. These results showed that ABL1 is involved in regulating the LSC compartment in BCR-ABL1 cells. DNA microarray analysis revealed changes in mRNA levels of several genes involved in proliferation, myeloid differentiation, apoptosis, DNA damage response and `stemness' in BCR-ABL1 Abl1-/- cells in comparison to BCR-ABL1 Abl1+/+ cells. Together, these results demonstrate a critical role of ABL1 as a tumor suppressor in BCR-ABL1-induced leukemia, prolonging survival in mice by suppressing proliferation and expansion of LSC, inducing myeloid differentiation, apoptosis and DNA damage response in BCR-ABL1 cells. Loss of ABL1 was also found to contribute to Imatinib resistance in BCR-ABL1 cells. Moreover, we hypothesized that enhancement of the tumor-suppressor function of ABL1 may have a significant impact on CML treatment. A small molecule activator of ABL1 kinase, 5-(1,3-diaryl-1H-pyrazol-4-yl)hydantoin (DPH), have been reported to interact with the myristoyl-binding site of ABL1 and destabilize the bent conformation of the á1 helix, thereby preventing the auto-inhibitory conformation. Western blot analysis revealed partially restored activation of ABL1 kinase when Imatinib-treated cells were incubated with DPH. DPH along with Imatinib was found to inhibit viability of BCR-ABL1 Abl1+/+ cells but not BCR-ABL1 Abl1-/- cells demonstrating its ABL1-specific mode of action. DPH when used in combination with tyrosine kinase inhibitors such as Imatinib and Ponatinib inhibited growth of CML CD34+ cells, Philadelphia chromosome-positive B-Acute Lymphoblastic Leukemia (Ph+B-ALL) cells and relapsed Ph+B-ALL cells harboring T315I mutation without affecting normal counterparts. A similar inhibitory effect was observed when TEL-ABL1-expressing cell lines and NUP214-ABL1-expressing murine bone marrow cells were treated with DPH and Imatinib, as well as Acute Myeloid Leukemia (AML) cells expressing FLT3-ITD mutation when treated with DPH in combination with AC220 which is the FLT3-ITD inhibitor. In summary, ABL1 is a potential tumor-suppressor in BCR-ABL1-induced leukemia and stimulation of its function may play a significant role in the development of novel therapeutic strategies for CML and other Fusion Tyrosine Kinase (FTK)-mediated hematologic malignancies.
Temple University--Theses
Maletzke, Saskia [Verfasser], Steffen [Akademischer Betreuer] Koschmieder, and Burkhard [Akademischer Betreuer] Gess. "Die duale Hemmung der BCR-ABL1 Kinase und des Proteasoms als neuer Therapieansatz in der BCR-ABL positiven akuten lymphatischen Leukämie / Saskia Maletzke ; Steffen Koschmieder, Burkhard Gess." Aachen : Universitätsbibliothek der RWTH Aachen, 2021. http://d-nb.info/1229991301/34.
Full textBerglind, Johan, and Markus Hansson. "Låneförbudet i ABL." Thesis, Örebro University, Department of Behavioural, Social and Legal Sciences, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-554.
Full textI den här uppsatsen har vi undersökt och behandlat låneförbudet som återfinns i ABL 12:7 och i kap 21 i nya ABL. Vi har undersökt om lagen uppfyller sina syften samt vilka syften som lagstiftaren har haft. Intressant är att en ny ABL träder i kraft den 1 januari 2006. Vi har utgått från lagstiftningen och sedan följt upp med rättspraxis och doktrin.
Under arbetets gång upptäckte vi luckor i lagstiftningen vilket medför att syftena bakom lagstiftningen inte kom till sin fulla rätt. Luckorna öppnar möjligheter att kringgå låneförbudet med tämligen enkla metoder. Vi har bland annat undersökt kringgående av lagstiftningen med hjälp utav efterföljande finansiering samt ett kringgående med hjälp av andra rättsobjekt.
Med efterföljande finansiering menas att ett bolag köps med bolagets egna pengar, med hjälp av undantaget för koncernlån. Ett kringgående med hjälp utav andra rättsobjekt kan se ut på lite olika sätt. I vårt arbete har vi använt av oss utav en fysisk person samt ett handelsbolag. Ett kringgående av lagstiftningen möjliggörs genom att andra rättsobjekt än aktiebolag ej lyder under aktiebolagslagen i stora drag.
Dessa handlingar rör sig inom ett grått område inom juridiken och gör låneförbudet till ett tämligen trubbigt redskap.
Eftersom låneförbudet tillhör specialstraffrätten möjliggörs kringgående av lagstiftningen då restriktiv lagtolkning måste användas. Faller en handling inte in ordagrant i vad som står i lagtexten är kringgåendet av låneförbudet både i nya och gamla ABL ett faktum.
Peters, Elaine. "Holistic Evaluation of Peer Writings by Able and Less Able Readers in Eighth and Tenth Grades." Thesis, North Texas State University, 1987. https://digital.library.unt.edu/ark:/67531/metadc331667/.
Full textJames, Sarah. "Please stand if you are able." College Park, Md. : University of Maryland, 2005. http://hdl.handle.net/1903/2499.
Full textThesis research directed by: Dept. of English. Title from t.p. of PDF. Includes bibliographical references. Published by UMI Dissertation Services, Ann Arbor, Mich. Also available in paper.
MacDonald, Craig. "Able autistic adults' constructions of social disability." Thesis, University of Leicester, 2002. http://hdl.handle.net/2381/31336.
Full textSpradlin, Cheryl E. Bialeschki M. Deborah. "They are able who think they are able an examination of the relationship between recreation therapy and selected psychological constructs /." Chapel Hill, N.C. : University of North Carolina at Chapel Hill, 2006. http://dc.lib.unc.edu/u?/etd,462.
Full textTitle from electronic title page (viewed Oct. 10, 2007). "... in partial fulfillment of the requirements for the degree of Master of Science in Recreation Administration in the Department of Exercise and Sport Science." Discipline: Recreation Administration; Department/School: Exercise and Sport Science.
Pereyra, Elías Reneé, Idrogo Juan José Montenegro, and Percy Mayta-Tristan. "Are medical students able to perform multicenter studies?" Medwave Estudios Limitada, 2015. http://hdl.handle.net/10757/579916.
Full textEargle, Ann. "Always Willing, Always Able: Living Beyond Your Means." Digital Commons @ East Tennessee State University, 2015. http://amzn.com/150249910X.
Full texthttps://dc.etsu.edu/etsu_books/1023/thumbnail.jpg
Domenie, Sanna. "Borgenärsskyddet i ABL : Konkurrenskraftiga regler?" Thesis, Stockholms universitet, Juridiska institutionen, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-95839.
Full textSchaller-Schönitz, Michael [Verfasser]. "Der Einfluss von BCR-ABL auf STAT5 in BCR-ABL-positiven Leukämiezellen / Michael Schaller-Schönitz." Hannover : Technische Informationsbibliothek und Universitätsbibliothek Hannover, 2011. http://d-nb.info/1012635929/34.
Full textSadeghi, Heydar. "Gait asymmetry in able-bodied subjects using biomechanic data." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/nq43032.pdf.
Full textSwist, Frédérique. "Between physics and art : imaging the un-image-able." Thesis, University of the West of England, Bristol, 2014. http://eprints.uwe.ac.uk/24106/.
Full textSwanepoel, Karel Albertus. "Being a paralympic athlete in an able-bodied world." Pretoria : [s.n.], 2008. http://upetd.up.ac.za/thesis/available/etd-11252008-133519.
Full textLeal, Caio Bruno Quinta de Souza. "AVALIAÇÃO DE DOENÇA RESIDUAL MÍNIMA EM PACIENTES COM LEUCEMIA MIELÓIDE CRÔNICA." Pontifícia Universidade Católica de Goiás, 2014. http://localhost:8080/tede/handle/tede/2387.
Full textMonitoring of minimal residual disease (MRD) in patients with Chronic Myeloid Leukemia (CML) who receive treatment with Imatib mesylate (IM) is extremely important, because it enables the evaluation of the response to the treatment and the early diagnosis of possible recurrences. The objective of this study was to standardize molecular methods used in order to monitor MRD in patients with CML, on therapy with IM. Peripheral blood samples were collected from 11 patients diagnosed with CML in October 2012 to September 2013, in the Department of Hematology of Hospital Araújo Jorge of the Association to Combat Cancer in Goiás. Three months after starting treatment, patients underwent a new peripheral blood collection for evaluation of MRD. Detecting bcr-abl transcripts and endogenous controls (abl and β2m) employed reverse transcription methods associated with polymerase chain reaction (RT-PCR), while quantification of bcr-abl transcripts was achieved by using reverse transcription associated with real-time PCR (RQ-PCR) and Taqman probes. Specific oligonucleotides and probes recognizing e13a2 and e14a2 junctions of bcr-abl transcripts and to the abl endogenous control were used in this study. By the time of diagnosis, three patients (27.3%) expressed the b2a2 transcript, five patients (45.5%) expressed the b3a2 transcript, two patients (18.2%) expressed both transcripts and one patient (9%) did not express any of the transcripts. The endogenous controls analysis resulted in better amplification for the abl transcript, which was used in the RQ-PCR reactions. The assessment of DRM was possible in only eight patients, due to the loss of follow-up. Three months after starting treatment with IM, all patients presented complete hematologic response. However, only one patient (12.5%) presented the undetectable transcript, reaching the full molecular response, while the other seven patients (87.95%) presented MRD. One (12.5%) of the seven patients who presented MRD, reached complete molecular response, while six patients (75%) presented a reduction of two logs, achieving minor molecular response, and one patient (12.5%) presented only partial molecular response. By using molecular biology methods, our results have enabled the standardization and the establishment of a laboratory routine, according to the international guidelines, for monitoring MRD in patients with CML.
O monitoramento de doença residual mínima (DRM) em pacientes com leucemia meilóide crônica (LMC) que recebem tratamento com mesilato de imatibe (MI) é extremamente relevante, pois possibilita o acompanhamento da resposta e o diagnóstico precoce de eventuais recidivas da doença. O objetivo deste estudo foi padronizar métodos moleculares utilizados na avaliação de DRM em pacientes com LMC, em tratamento com MI. Amostras de sangue periférico foram coletadas de 11 pacientes diagnosticados com LMC, no período de outubro de 2012 a setembro de 2013, no Setor de Hematologia do Hospital Araújo Jorge da Associação de Combate ao Câncer em Goiás. Três meses após o início do tratamento, os pacientes foram submetidos a uma nova coleta de sangue periférico para avaliação de DRM. A detecção dos transcritos bcr-abl e controles endógenos (abl e β2m) empregaram os métodos de transcrição reversa associados à reação em cadeia da polimerase (RT-PCR), enquanto a quantificação dos transcritos bcr-abl foi feita por meio de transcrição reversa associada à PCR em tempo real (RQ-PCR), utilizando a metodologia de sondas de hidrólise (TaqMan). Oligonucleotídeos e sondas Taqman específicos para as junções e13a2 e e14a2 dos transcritos bcr-abl e para o controle endógeno (abl) foram usados neste estudo. Ao diagnóstico, três pacientes (27,3%) expressaram o transcrito b2a2, cinco pacientes (45,5%) o transcrito b3a2, dois pacientes (18,2%) expressaram ambos os transcritos e um paciente (9%) não expressou nenhum dos transcritos. A amplificação dos controles endógenos resultou em melhor amplificação para o transcrito abl, que foi usado nas reações de RQ-PCR. A avaliação de DRM foi possível em oito pacientes, devido à perda de seguimento dos demais. Três meses após o início do tratamento com MI, todos os pacientes apresentaram resposta hematológica completa. No entanto, apenas um paciente (12,5%) apresentou o transcrito bcr-abl indetectável, alcançando a reposta molecular completa, enquanto os outros sete pacientes (87,95%) apresentaram DRM. Dentre os sete pacientes que apresentaram DRM, seis (75%) apresentaram redução de um a dois logs, alcançando resposta molecular menor, enquanto um (12,5%) apresentou resposta molecular parcial. Nossos resultados possibilitaram a padronização e o estabelecimento de uma rotina segundo as diretrizes internacionais, para monitoramento da DRM em pacientes com LMC, utilizando métodos de biologia molecular
Sjöstrand, Janna. "Jämkningsreglerna i ABL och 36 § AvtL." Thesis, Högskolan i Jönköping, Internationella Handelshögskolan, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:hj:diva-15580.
Full textAlexander, Keith. "Projecting proteins and random walks : knotting in open curves via virtual knots." Thesis, University of Bristol, 2018. http://hdl.handle.net/1983/f630898a-6e6b-476e-abf2-e9ff95d5671c.
Full textBrook, Madeleine E. "Popular history and fiction : the myth of August the Strong in German literature, art, and media." Thesis, University of Oxford, 2011. http://ora.ox.ac.uk/objects/uuid:cb7df46e-ab52-4f27-a084-41d7fab5b54e.
Full textRees, Timothy John. "Agrarian society and politics in the province of Badajoz under the Spanish Second Republic, 1931-1936." Thesis, University of Oxford, 1991. http://ora.ox.ac.uk/objects/uuid:a9a57d34-b448-434e-ab32-726a19aeffea.
Full textWebster, Thomas Kuli. "International and national influences on universal primary education policies, with special reference to Papua New Guinea." Thesis, University of Bristol, 1997. http://hdl.handle.net/1983/1596bcb4-ab42-4dcb-90f8-9c401b82b165.
Full textBaig, Shabnam Mobeen. "The extracellular matrix in Alzheimer's disease." Thesis, University of Bristol, 2006. http://hdl.handle.net/1983/f7eb48ef-9368-4f28-ab12-738fb9e517b5.
Full textKapitan, Daniel. "Laser ablation with copper vapour lasers." Thesis, University of Oxford, 1999. https://ora.ox.ac.uk/objects/uuid:a1dc1a3b-602a-4ebb-abe2-734e8e11f15a.
Full textHeddle, Catherine. "Study of an Arthrobacter sp. esterase able to hydrolyse malathion." Thesis, University of Leicester, 1997. http://hdl.handle.net/2381/29622.
Full textVause, Tricia. "Relationships between ABLA test performance, auditory matching, and communication ability." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape15/PQDD_0005/MQ32275.pdf.
Full textMoreno, Rui Paolo Jinó. "Performance of the ICU are we able to measure it? /." [S.l. : [Groningen] : s.n.] ; [University Library Groningen] [Host], 1997. http://irs.ub.rug.nl/ppn/164409947.
Full textSvensson, Emma. "Förskottsutdelning och anteciperad vinstutdelning : Särskilt om förenligheten med ABLs borgenärsskydd." Thesis, Uppsala universitet, Juridiska institutionen, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-253666.
Full textSmith, K. L. "Co-construction of narrative in verbally able children with autism." Thesis, University College London (University of London), 2007. http://discovery.ucl.ac.uk/1444081/.
Full textToney, Megan. "Adaptation of locomotor control in able and impaired human walking." Diss., Georgia Institute of Technology, 2014. http://hdl.handle.net/1853/54003.
Full textSantone, Melissa. "A new TLR2 agonist is able to promote cross-presentation." Doctoral thesis, Università degli studi di Padova, 2013. http://hdl.handle.net/11577/3422606.
Full textSi definisce “Cross-presentazione” il meccanismo attraverso il quale le Cellule Presentanti l’Antigene (APCs) sono capaci di catturare, processare e caricare sul complesso MHC di classe I peptidi derivanti da un antigene extracellulare, inducendo una risposta citotossica da parte dei linfociti T CD8+. La risposta citotossica è di particolare importanza per lo sviluppo di vaccini antitumorali e antivirali, per i quali è necessaria un’attivazione delle cellule T CD8+. Come indurre la cross-presentazione ha quindi stimolato grande interesse da parte delle industrie farmaceutiche per lo sviluppo di questi vaccini. Una strategia promettente è l’utilizzo di adiuvanti, molecole aggiunte ai vaccini per modulare la risposta immunitaria e aumentare la protezione. La scoperta che composti con funzioni adiuvanti legassero i recettori di tipo Toll (TLRs), recettori coinvolti nel riconoscimento di motivi molecolari comuni a molti microrganismi patogeni, ha sollevato l’interesse verso lo sviluppo di una nuova famiglia di adiuvanti basati sull’attivazione dei pathways dei TLRs. Lo scopo del mio progetto di Dottorato è investigare se un nuovo composto, agonista del TLR2 (SMIP2.1), può aumentare la cross-presentazione di un antigene esogeno alle cellule T CD8+. SMIP2-1 è un lipopeptide di sintesi, identificato attraverso uno screening effettuato al Genomic Institute of Novartis Research Foundation, che Novartis Vaccines intende utilizzare come adiuvante. Utilizzando Ovalbumina (OVA) come antigene esogeno, abbiamo osservato che l’immunizzazione con OVA + SMIP2.1, sia di topi transgenici con un TCR specifico per OVA che di topi wild type, aumenta la risposta T CD8+ in termini di proliferazione, produzione di citochine e attività citotossica, rispetto a topi vaccinati solo con l’antigene. Inoltre, SMIP2.1 induce un’ottima risposta anticorpale contro l’antigene, caratteristica fondamentale di un adiuvante. Utilizzando cellule tumorali murine che esprimono OVA, abbiamo osservato che la risposta citotossica indotta dall’agonista del TLR2 è capace di inibire la crescita tumorale in vivo. Un meccanismo attraverso cui SMIP2.1 aumenta la risposta immunitaria potrebbe essere la sua abilità di aumentare la deposizione dell’antigene nei linfonodi drenanti sul sito di iniezione e l’uptake dell’antigene da parte delle APCs, come dimostrato dalle osservazioni al microscopio confocale. Abbiamo poi analizzato quale popolazione cellulare può cross-presentare in vitro, scoprendo che sia le cellule dendritiche CD8+ e CD8- sono capaci di cross-presentare dopo stimolazione con SMIP2.1. Per valutare l’effetto dell’agonista del TLR2 su cellule umane, abbiamo usato un’analisi al citofluorimetro per misurare l’attivazione delle cellule T CD8+ isolate dai PBMC di pazienti positivi per il Citomegalovirus. Abbiamo trovato che SMIP2.1 aumenta la capacità delle APC umane, stimolate in vitro con la proteina pp65 del CMV, di attivare una popolazione T CD8+ specifica per il CMV. In conclusione, i nostri dati dimostrano che la vaccinazione con una proteina esogena formulata con SMIP2.1 è una promettente strategia per indurre sia una risposta citotossica che una risposta anticorpale.
Harnois, Thomas. "Interaction et activation différentielles des petites protéines G de la famille rho par p210bcr-abl et p190bcr-abl." Poitiers, 2004. http://www.theses.fr/2004POIT2258.
Full textThe Philadelphia chromosome associated with several leukaemia results a reciprocal translocation between the Abl gene on chromosome 9 and the Bcr gene on chromosome 22. Depending on locations of the breakpoint on the BCR genome, there are two alternative forms of BCR-ABL: p210bcr-abl, found in chronic myelogenous leukemia (CML), and p190bcr-abl, found in acute lymphocytic leukemia (ALL). The only difference between both forms of Bcr-Abl is the absence of the DH domain of Bcr in the form p190bcr-abl. The present work showed interactions and activation of Rho family GTPases by Bcr-Abl thanks to techniques of coimmunoprecipitation, pull-down, GEF activity and confocal microscopy. We can demonstrate that p210bcr-abl interacts and activates RhoA, Rac1 and Cdc42. In spite of the lack of a GEF domain, the p190bcr-abl is able to activate Rac1 and Cdc42. This GEF activity from p190bcr-abl seems to come from partners associated like Vav protein having an GEF activity from Rac1 and Cdc42. We showed the Vav protein presence in complex in the form activated with Bcr-Abl. In contrast, p210bcr-abl is able to activate directly RhoA by the GEF domain of Bcr. These results allowed to set up a model of development of leukaemia Philadelphia chromosome, in which Rac1 and Cdc42 activated by p190bcr-abl and p210bcr-abl are implicated in the cellular transformation (in inhibition of apoptosis, cell motility and proliferation). Whereas the specific activation of RhoA by p210bcr-abl regulated the myeloid cell differentiation, that is the characteristic during the chronic phase of the CML
SILVA, David Rafael de Barros. "Modelo de hubbard estendido na cadeia ab2." Universidade Federal de Pernambuco, 2008. https://repositorio.ufpe.br/handle/123456789/6257.
Full textFaculdade de Amparo à Ciência e Tecnologia do Estado de Pernambuco
Nesta dissertação estudamos o modelo de Hubbard estendido na cadeia AB2. O hamiltoniano do modelo contém um termo cinético, parametrizado por t, e dois termos de repulsão coulombiana,U (intra-sítio) eV (inter-sítio). Considerando uma simetria de troca local peculiar desta cadeia, bem como simetrias globais do hamiltoniano de Hubbard, utilizamos o método numérico do grupo de renormalização da matriz densidade com condições de contorno abertas e número de estados máximo, M =200, focalizando nossos esforços na determinação do estado fundamental do sistema. Obtivemos o diagrama de fases produzido pela competição entre U e V em condições de semi-preenchimento de banda, um elétron por sítio. Confrontamos nossos resultados, obtidos para um sistema de vinte e quatro células, com aqueles obtidos pelo método de diagonalização exata para um sistema com seis células. Foram identificadas três regiões relevantes: para V . U/4 encontramos uma fase ferrimagnética, que é uma continuação da fase encontrada em V = 0, a qual se enquadra no conhecido teorema de Lieb; para V & U/4, foram caracterizadas regiões de separação de fases com a coexistência de uma região isolante (paramagnética) e metálica (ferromagnética), e uma fase reminiscente daquela encontrada para U = 0. A caracterização das regiões foi realizada através da medida dos perfis de carga e de spin, bem como pelo estudo da energia em função dos parâmetros do modelo
APONTE, Diego Alejandro Cogollo. "Modelo de Hubbard estendido na cadeia AB2." Universidade Federal de Pernambuco, 2005. https://repositorio.ufpe.br/handle/123456789/6786.
Full textNesta dissertação estudamos o hamiltonianano estendido de Hubbard através do método de diagonalização exata de Lanczos, em condição de contorno periódica, com foco na caracterização das propriedades magnéticas e de condução do estado fundamental da cadeia quântica AB2, nos diferentes regimes (forte, intermediário, fraco) de repulsão coulombiana local U e intersítio V, em semi-preenchimento da banda. Seguindo o mesmo procedimento caracterizamos o estado fundamental para a cadeia linear, comparando nossos resultados testes com aqueles já reportados na literatura. A inclusão da interação V, não considerada em estudos anteriores na cadeia AB2, deu origem a um novo diagrama de fases no plano (U,V), o qual exibe uma similitude não trivial com o diagrama obtido para a cadeia linear. No regime de acoplamento coulombiano U~>5t e para V<~/4, nosso sistema está numa fase ferrimagnética (FERRI), com a carga homogeneamente distribuída em cada sub-rede, e magnetizações locais < SzA > =~ -0.25 e < SZB > =~ 0.75. Para V~>/4, o sistema se encontra em uma fase onda de densidade de carga com ordem ferromagnética (ODCF), tal que < SzA > =0 e < SZB>=0.5, exibindo um defeito na distribuição de carga. No regime de acoplamento coulombiano U~<5t, o sistema exibe uma fase intermediária com correlação magnética tipo Espiral. Neste regime o spin salta do valor 1/2 por célula unitária, na fase FERRI, para zero na fase Espiral, e de zero ao valor de 1/2 por célula unitária na fase ODCF. Nossa análise de escala de tamanho finito indica que as duas transições são de primeira ordem no campo de spin. Examinamos também a natureza das fases mencionadas com respeito às propriedades de condução, assim como a ocorrência de um ponto multicrítico na linha V≈U /4 para U≈5t
Zeng, Yi. "Optimizing immunity against BCR-ABL positive leukemia." Diss., The University of Arizona, 2003. http://hdl.handle.net/10150/289963.
Full textSandström, Glenn. "Ready, Willing and Able : The Divorce Transition in Sweden 1915-1974." Doctoral thesis, Umeå universitet, Centrum för befolkningsstudier (CBS), 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-60216.
Full textRönneke-Widerström, Alexander. "Are students in high school able to comprehend Garden-path sentences?" Thesis, Linnéuniversitetet, Institutionen för språk och litteratur, SOL, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-13244.
Full textUsmani, Wali Ahmed. "Not able to resist the urge : social insider attacks on Facebook." Thesis, University of British Columbia, 2016. http://hdl.handle.net/2429/60294.
Full textScience, Faculty of
Computer Science, Department of
Graduate
Onken, Brian. "Able to teach an analysis of didaktikos in the Pastoral Epistles /." Theological Research Exchange Network (TREN), 1987. http://www.tren.com.
Full textCorry, Val. "Academically able boys' perceptions of their learning : a grounded theory analysis." Thesis, University of Glasgow, 2017. http://theses.gla.ac.uk/8094/.
Full textEiler, Brian A. "What it Means to be Interact-able: A Social Affordance Perspective." University of Cincinnati / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1447688671.
Full textWang, Chuan. "Development of plough-able RFID sensor network systems for precision agriculture." Thesis, University of Manchester, 2016. https://www.research.manchester.ac.uk/portal/en/theses/development-of-ploughable-rfid-sensor-network-systems-for-precision-agriculture(d19815ad-8a07-458f-8836-c0ddf7c8dc7a).html.
Full textMartinsson, Erik. "Förenklade regler i ABL : För små privata aktiebolag." Thesis, Jönköping University, JIBS, Commercial Law, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:hj:diva-12248.
Full textDen som vill bedriva näringsverksamhet i Sverige kan välja mellan olika bolagsformer, däribland enskild firma, handelsbolag eller aktiebolag. Det finns två typer av aktiebolag, privata och publika, de regleras av bestämmelserna i aktiebolagslagen och aktiebolagsförordningen. Bestämmelserna i dessa författningar härstammar till viss del från de bolagsrättsliga direktiv som EU har beslutat ska gälla inom unionen.
Det sker ständiga förändringar på bolagsrättens område, både avseende de gemenskapsrättsliga reglerna från EU och de nationella bestämmelserna i Sverige. Europeiska kommissionen har ansett det som nödvändigt att även se över samtliga bolagsdirektiv för att underlätta det administrativa arbete som åligger, framförallt, mindre bolag inom unionen. Kommissionen ansåg även i samma utredning det angeläget att varje medlemsstat såg över deras nationella regelverk för att minska den administrativa bördan för små bolag.
Sveriges regering utfärdade i september 2007 ett direktiv till syfte att minska den administrativa bördan och skapa enklare regler för små privata aktiebolag. Utredningens resultat var färdigt i april 2009 och presenterades i SOU 2009:34. Resultatet av utredningen omfattar flertalet förändringar vad gäller såväl aktiebolagslagen som aktiebolagsförordningen. Det är målsättningen regeringen hade med utredningen och de förenklingar som föreslås som är föremål för denna uppsats. Syftet med uppsatsen är att analysera tre av förändringarna och förenklingarna. De tre områden som kommer att behandlas i denna uppsats är bolagets bildande, aktiebrev och aktiebok samt bolagets organisation. Uppsatsen kommer att utgå ifrån den målsättning regeringen hade när de tillsatte en utredning nämligen att minska små privata aktiebolags administrativa bördor och kostnader, att få ekonomisk tillväxt och ökad sysselsättning samt att de förenklingar som föreslås inte får sänka skyddet för borgenärer, arbetet mot ekonomisk brottslighet eller skattekontroll.
De slutsatser som presenteras i denna uppsats är att förenklingarna som utredningen har föreslagit uppfyller den målsättning som regeringen hade när de tillsatte en utredare. Enligt författarens mening finns det dock vissa andra områden som utredaren kunde ha undersökt då det finns en tydlig problematik avseende bland annat möjligheter till utträde ur ett privat aktiebolag. Det ska även nämnas att utredningen enbart behandlar de bolagsrättsliga reglerna, det finns andra regler som kan vara av intresse att utreda, till exempel skatteregler för privata aktiebolag.
A person who wants to run business in Sweden can choose between different types of associations, including sole trading, partnerships or limited liability companies. There are two types of limited liability companies in Sweden, private and public, which are governed by the provisions of the Companies Act and the Companies ordinance. Parts of the provisions in these two regulations are derived from directives on corporate law that the EU has decided shall apply in the union.
There are constant changes in corporate law regarding both the legal provisions from the EU and due to changes in the national legislation in Sweden. The European Commission has considered it necessary to review all corporate law directives in order to ease the administrative work for, in particular, smaller companies within the Union. The Commission also indicated in the same decision that it is necessary for each member state to review and reduce the administrative burden for small companies due to the national legislation.
The Swedish Government issued a directive in September 2007 with the aim to reduce the administrative burden and to create simpler rules for small private limited liability companies. The result of the directive was completed in April 2009 and was presented in SOU 2009:34. The investigations result included several changes both to the Swedish Companies Act and Companies Ordinance. It is the purpose that the Government had when they appointed an investigation that is the subject of this thesis. The purpose of this thesis is to analyze three of the changes that the investigation has presented. The three changes that will be subject to this thesis is the establishment of a company, the share certificates and share register and companies organization. The thesis will be based on three goals that the government had when they set up an investigation, to reduce the administrative burden and cost for small private limited liability companies, to establish economic growth and increase employment and finally not to reduce the protection for creditors and the work against economic crime.
The conclusion presented in this thesis is that the simplifications that the investigation had as purpose to fulfil, partially meets the goal the Government had. According to the author's opinion there are some areas that the investigation could have reviewed, such as the possibility for a shareholder to sell the shares in a private limited liability company.
Warmuth, Markus. "Src-Kinasen als Mediatoren Bcr-Abl-induzierter Leukämien." Diss., lmu, 2002. http://nbn-resolving.de/urn:nbn:de:bvb:19-2459.
Full textVidjeskog, Sandra. "Tredjemansskyddet i publicitetsreglerna 27 kap. ABL- En analys." Thesis, Uppsala universitet, Juridiska institutionen, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-192357.
Full textHübinette, Isak. "Kapitalbristreglerna i ABL : ett otillräckligt borgenärsskydd i praktiken." Thesis, Stockholms universitet, Juridiska institutionen, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-115546.
Full textBoulter, C. A. "Expression of SRC and ABL during mouse development." Thesis, University College London (University of London), 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.382648.
Full text